#pertuzumab

CHICAGO — An “adaptive response” treatment strategy identified a subset of patients with HER2-positive early breast cancer who benefited from a chemotherapy-free treatment plan, according to the phase II PHERGain trial. The strategy is based on evaluating an early response to a dual HER2 blockade with trastuzumab (Herceptin) and pertuzumab (Perjeta) with 18F-FDG PET imaging and postsurgical…

Pertuzumab, also known as Perjeta, is a monoclonal antibody that is used in conjunction with trastuzumab and docetaxel to treat metastatic HER2-positive breast cancer. It is also utilised as a neoadjuvant in early HER2-positive breast cancer.

More than half of those who take it experience diarrhoea, hair loss, and neutrophil loss; more than 10% experience red blood cell loss, hypersensitivity or allergic reaction, infusion reactions, decreased appetite, insomnia, taste distortions, mouth or lip inflammation, constipation, rashes, nail disease, and muscle pain. 

It should not be taken by women who are pregnant or planning to get pregnant; it has not been examined in people with specific heart disorders and should be used with caution in these individuals; and it should not be taken with an anthracycline. Pertuzumab interaction with doxorubicin is uncertain.

And now a ‘quicker, kinder’ breast cancer treatment

A new five-minute breast cancer treatment is being rolled out in England in a bid to dramatically reduce the amount of time patients spend in hospital, The Telegraph reports. More than 3,600 women a year are expected to benefit from the injection, which combines two drugs currently administered as separate intravenous infusions, says Yahoo News, quoting the medium. Treatment with the prescription…

Pertuzumab is a recombinant monoclonal antibody that acts as an antineoplastic agent, which targets the human epidermal growth factor receptor 2 protein known as HER2. The drug blocks signaling pathways that leads to cell growth arrest and apoptosis (cell destruction), thereby inhibiting the proliferation of human tumor cells. Pertuzumab was found to aid in the treatment of HER2 associated breast cancer and was developed by Genentech, Inc., a subsidiary of F. Hoffmann-La Roche AG. It was first approved by U.S. Food and Drug Administration in 2012.

Download PDF Brochure Of This Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/2256

Pertuzumab Market– Drivers

There are increasing number of clinical trials for use of pertuzumab in combination with other drugs for the treatment of breast cancer . For instance, Helsinki University Central Hospital is undergoing phase III clinical study for adjuvant trastuzumab, pertuzumab, and docetaxel in the treatment of early HER2 positive breast cancer. The study was started in December 2015 and is estimated to complete by June 2023.

Pertuzumab Market– Restraint

Increasing cost of anticancer drugs is expected to be a major factor hampering growth of the market. For instance, in June 2017, The Scottish Medicines Consortium (SMC) denied access to pertuzumab in England, which was available via the Cancer Drugs Fund (CDF) in Europe. The drug was rejected by SMC as the treatment of HER2 positive breast cancer was not cost effective when pertuzumab was used in combination with trastuzumab and docetaxel.

Pertuzumab market – Competitive Analysis

Pertuzumab Industry: Global Market Trends, Share, Size and Forecast Report 2018-2025

This report studies the global Pertuzumab market status and forecast, categorizes the global Pertuzumab market size (value & volume) by manufacturers, type, application, and region. This report focuses on the top manufacturers in North America, Europe, Japan, China, and other regions (India, Southeast Asia).

The major manufacturers covered in this report  Novartis AG Pfizer Abnova Corporation Invi…

Roche, insieme al Breast International Group (BIG), al Breast European Adjuvant Study Team (BrEAST) e alla fondazione Frontier Science (FS) annunciano i risultati positivi dello studio di Fase III, APHINITY.

Lo studio ha soddisfatto il suo endpoint primario e ha mostrato che il trattamento adiuvante (dopo l’intervento chirurgico) con l’associazione di pertuzumab, trastuzumab e chemioterapia ha…